| Literature DB >> 18389384 |
Marjan J Westerman1, Tony Hak, Mirjam A G Sprangers, Harry J M Groen, Gerrit van der Wal, Anne-Mei The.
Abstract
BACKGROUND: Quality of life (QoL) is considered to be an indispensable outcome measure of curative and palliative treatment. However, QoL research often yields findings that raise questions about what QoL measurement instruments actually assess and how the scores should be interpreted.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18389384 PMCID: PMC2358935 DOI: 10.1007/s11136-008-9333-6
Source DB: PubMed Journal: Qual Life Res ISSN: 0962-9343 Impact factor: 4.147
Individual and mean scores of patients answering the EORTC QLQ-C30 questions on physical functioning (PF), role functioning (RF), and global health (GH) and quality of life (QOL)
| Patient characteristics | T1 ( | T2 ( | T3 ( | T4 ( | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | M/F | Age | LD/ED | GH/QOL | PF | RF | GH/QOL | PF | RF | GH/QOL | PF | RF | GH/QOL | PF | RF |
| P 12 | F | 47 | LD | 83 | 100 | 100 | 100 | 100 | 67 | 66 | 100 | 67 | 83 | 93 | 33 |
| P 04 | F | 50 | LD | 83 | 94 | 67 | – | – | – | 33 | 67 | 83 | 67 | 87 | 83 |
| P 24 | F | 56 | LD | 83 | 100 | 50 | 75 | 93 | 100 | 92 | 93 | 67 | 100 | 100 | 100 |
| P 17 | F | 64 | ED | 83 | 80 | 83 | 83 | 80 | 67 | 83 | 40 | 67 | # | # | # |
| P 03 | F | 64 | ED | 83 | 67 | 33 | – | – | – | 58 | 40 | 0 | 50 | 60 | 33 |
| P 34 | F | 51 | LD | 75 | 100 | 83 | 83 | 100 | 100 | 92 | 100 | 100 | 100 | 100 | 100 |
| P 15 | F | 69 | LD X* | 75 | 93 | 83 | 50 | 60 | 67 | 42 | 80 | 67 | 83 | 93 | 100 |
| P 01 | F | 42 | LD X* | 66 | 73 | 50 | – | – | – | 50 | 60 | 34 | 83 | 87 | 67 |
| P 20 | F | 44 | LD X* | 66 | 87 | 100 | 42 | 73 | 0 | 42 | 80 | 50 | 33 | 47 | 0 |
| P 32 | F | 60 | LD | 66 | 87 | 83 | 100 | 67 | 100 | 83 | 67 | 100 | 83 | 53 | 100 |
| P 26 | F | 59 | LD X* | 58 | 42 | 56 | 92 | 93 | 100 | 75 | 92 | 83 | – | – | – |
| P 08 | F | 69 | ED | 50 | 80 | 83 | 33 | 60 | 100 | 75 | 73 | 100 | 83 | 67 | 50 |
| P 22 | M | 55 | LD X* | 75 | 73 | 67 | 83 | 75 | 67 | 50 | 60 | 100 | – | – | – |
| P 21 | M | 69 | ED | 75 | 47 | 50 | 83 | 60 | 83 | 83 | 87 | 100 | 83 | 93 | 83 |
| P 10 | M | 46 | LD X* | 66 | 87 | 67 | 83 | 87 | 67 | 83 | 93 | 83 | 83 | 93 | 83 |
| P 09 | M | 66 | ED | 66 | 100 | 50 | 83 | 92 | 0 | 92 | 67 | 67 | 75 | 73 | 100 |
| P 16 | M | 68 | LD X* | 66 | 67 | 100 | 75 | 73 | 67 | 58 | 67 | 67 | 75 | 87 | 100 |
| P 18 | M | 72 | ED | 66 | 73 | 67 | 50 | 67 | 17 | 50 | 60 | 100 | 66 | 67 | 100 |
| P 29 | M | 63 | ED | 50 | 80 | 50 | 50 | 80 | 67 | 58 | 83 | 33 | 75 | 87 | 100 |
| P 27 | M | 69 | LD | 50 | 53 | 33 | 66 | 53 | 50 | 66 | 67 | 50 | 66 | 80 | 83 |
| P 13 | M | 72 | ED | 50 | 53 | 33 | 66 | 60 | 67 | 66 | 60 | 67 | 42 | 67 | 33 |
| P 02 | M | 57 | ED | 42 | 40 | 33 | – | – | – | 58 | 67 | 100 | # | # | # |
| P 14 | M | 39 | LD | 33 | 53 | 0 | 66 | 73 | 83 | 58 | 60 | 67 | # | # | # |
| All patients | GH/QOL | PF | RF | GH/QOL | PF | RF | GH/QOL | PF | RF | GH/QOL | PF | RF | |||
| Mean score | 66 | 75 | 62 | 72 | 76 | 67 | 66 | 72 | 72 | 68 | 80 | 75 | |||
Small-cell lung cancer patients (n = 23), limited (LD) and extensive (ED) disease receiving 1st line chemotherapy were interviewed at equivalent points in treatment: at start of chemotherapy (T1), 4 weeks later (T2), at end of chemotherapy (T3), and 6 weeks later (T4). Three patients died before T4 (#). Scores range from 0 to 100; higher scores represent a higher level of functioning. Seven patients with limited disease were treated with chemotherapy and radiation therapy (LD X*)
Fig. 1Examples of response strategies used to answer question 1, 2, 4, 6, and 7 of the EORTC-QLQC30 questionnaire. These strategies and change in the use of a certain strategy over time may explain why patients do not report the deterioration in physical and role functioning that would objectively be expected